| abstract |
The present invention provides an arthritis supplement therapy for treating osteoarthritis and joint damage using an HA-based arthritis supplement, in particular an articular supplement with an intraarticular retention half-life of less than three weeks. The joint fluid supplement used in the method of the present invention is further characterized by containing less than 20 mg / ml of HA, wherein at least 5% (w / w) of such HA is in gel form, for example, Hailan B. In an exemplary embodiment, Hailan G-F 20 (Synvisc®) is administered in one intra-articular knee injection of 6 ± 2 ml. |